Drug Information
Drug (ID: DG01523) and It's Reported Resistant Information
Name |
GDC0879
|
||||
---|---|---|---|---|---|
Synonyms |
GDC-0879; 905281-76-7; (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime; CHEBI:83405; GDC0879; UNII-E488J6BA6E; (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime; CHEMBL525191; E488J6BA6E; GDC 0879; 2-[4-[(1E)-1-hydroxyimino-2,3-dihydroinden-5-yl]-3-pyridin-4-ylpyrazol-1-yl]ethanol; 2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1h-pyrazol-4-yl)-1h-inden-1-one oxime; 2,3-Dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-1H-inden-1-one oxime; 2-{4-[(1e)-1-(Hydroxyimino)-2,3-Dihydro-1h-Inden-5-Yl]-3-(Pyridin-4-Yl)-1h-Pyrazol-1-Yl}ethanol; SCHEMBL2467603; DTXSID00471110; BCPP000222; AMY20724; EX-A2357; GDC-0879,GDC0879; BDBM50029085; s1104; ZINC34640412; AKOS015856553; BCP9000714; CCG-264821; CS-0158; NCGC00263179-09; HY-50864; QC-11137; BCP0726000314; DB-000743; GDC-0879, >=98% (HPLC); X7405; EC-000.2334; J-506998; BRD-K67578145-001-01-4; BRD-K67578145-001-12-1; (E)-5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one; (E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-oneoxime; 5-(1-(2-Hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime; 5-[1-(2-Hydroxy-ethyl)-3-pyridin-4-yl-1H-pyrazol-4-yl]-indan-1-one oxime; 1H-Inden-1-one, 2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl)-, oxime; 1H-Inden-1-one, 2,3-dihydro-5-(1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl)-, oxime, (1E)-; 2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-pyridin-4-yl-1H-pyrazol-1-yl}ethanol;(E)-5-(1-(2-hydroxyethyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime; 2230954-03-5
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug
(3 diseases)
Colon cancer [ICD-11: 2B90]
[1]
Lung cancer [ICD-11: 2C25]
[1]
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
[2]
|
||||
Target | Serine/threonine-protein kinase B-raf (BRAF) | BRAF_HUMAN | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
4
|
||||
IsoSMILES |
C1C/C(=N\\O)/C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO
|
||||
InChI |
InChI=1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2/b22-18+
|
||||
InChIKey |
DEZZLWQELQORIU-RELWKKBWSA-N
|
||||
PubChem CID |
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [2] | |||
Molecule Alteration | Missense mutation | p.F53L (c.157T>C) |
||
Resistant Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293 cells | Kidney | Homo sapiens (Human) | CVCL_0045 |
Experiment for Molecule Alteration |
SDS-PAGE assay | |||
Mechanism Description | The missense mutation p.F53L (c.157T>C) in gene MAP2K1 cause the resistance of GDC0879 by unusual activation of pro-survival pathway | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [2] | |||
Molecule Alteration | Missense mutation | p.Q56P (c.167A>C) |
||
Resistant Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293 cells | Kidney | Homo sapiens (Human) | CVCL_0045 |
Experiment for Molecule Alteration |
SDS-PAGE assay | |||
Mechanism Description | The missense mutation p.Q56P (c.167A>C) in gene MAP2K1 cause the resistance of GDC0879 by unusual activation of pro-survival pathway | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [2] | |||
Molecule Alteration | Missense mutation | p.K57N (c.171G>C) |
||
Resistant Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293 cells | Kidney | Homo sapiens (Human) | CVCL_0045 |
Experiment for Molecule Alteration |
SDS-PAGE assay | |||
Mechanism Description | The missense mutation p.K57N (c.171G>C) in gene MAP2K1 cause the resistance of GDC0879 by unusual activation of pro-survival pathway | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [2] | |||
Molecule Alteration | Missense mutation | p.I111S (c.332T>G) |
||
Resistant Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293 cells | Kidney | Homo sapiens (Human) | CVCL_0045 |
Experiment for Molecule Alteration |
SDS-PAGE assay | |||
Mechanism Description | The missense mutation p.I111S (c.332T>G) in gene MAP2K1 cause the resistance of GDC0879 by unusual activation of pro-survival pathway | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [2] | |||
Molecule Alteration | Missense mutation | p.C121S (c.361T>A) |
||
Resistant Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293 cells | Kidney | Homo sapiens (Human) | CVCL_0045 |
Experiment for Molecule Alteration |
SDS-PAGE assay | |||
Mechanism Description | The missense mutation p.C121S (c.361T>A) in gene MAP2K1 cause the resistance of GDC0879 by unusual activation of pro-survival pathway | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [2] | |||
Molecule Alteration | Missense mutation | p.F129L (c.385T>C) |
||
Resistant Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293 cells | Kidney | Homo sapiens (Human) | CVCL_0045 |
Experiment for Molecule Alteration |
SDS-PAGE assay | |||
Mechanism Description | The missense mutation p.F129L (c.385T>C) in gene MAP2K1 cause the resistance of GDC0879 by unusual activation of pro-survival pathway | |||
Key Molecule: MAPK/ERK kinase 1 (MEK1) | [2] | |||
Molecule Alteration | Missense mutation | p.V211D (c.632T>A) |
||
Resistant Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293 cells | Kidney | Homo sapiens (Human) | CVCL_0045 |
Experiment for Molecule Alteration |
SDS-PAGE assay | |||
Mechanism Description | The missense mutation p.V211D (c.632T>A) in gene MAP2K1 cause the resistance of GDC0879 by unusual activation of pro-survival pathway |
Colon cancer [ICD-11: 2B90]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
Molecule Alteration | Missense mutation | p.N581Y (c.1741A>T) |
||
Resistant Disease | Colon cancer [ICD-11: 2B90.1] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vivo Model | Female nu/nu mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunoblotting assay | |||
Experiment for Drug Resistance |
CellTiter-Glo assay | |||
Mechanism Description | The missense mutation p.N581Y (c.1741A>T) in gene BRAF cause the resistance of GDC0879 by aberration of the drug's therapeutic target |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
Molecule Alteration | Missense mutation | p.V600E (c.1799T>A) |
||
Sensitive Disease | Colon cancer [ICD-11: 2B90.1] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vivo Model | Female nu/nu mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunoblotting assay | |||
Experiment for Drug Resistance |
CellTiter-Glo assay | |||
Mechanism Description | The missense mutation p.V600E (c.1799T>A) in gene BRAF cause the sensitivity of GDC0879 by aberration of the drug's therapeutic target |
Lung cancer [ICD-11: 2C25]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
Molecule Alteration | Missense mutation | p.L485Y (c.1454_1455delTGinsAT) |
||
Resistant Disease | Lung adenocarcinoma [ICD-11: 2C25.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vivo Model | Female nu/nu mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunoblotting assay | |||
Experiment for Drug Resistance |
CellTiter-Glo assay | |||
Mechanism Description | The missense mutation p.L485Y (c.1454_1455delTGinsAT) in gene BRAF cause the resistance of GDC0879 by aberration of the drug's therapeutic target |
Melanoma [ICD-11: 2C30]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
Molecule Alteration | Missense mutation | p.V600E (c.1799T>A) |
||
Sensitive Disease | Melanoma [ICD-11: 2C30.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vivo Model | Female nu/nu mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunoblotting assay | |||
Experiment for Drug Resistance |
CellTiter-Glo assay | |||
Mechanism Description | The missense mutation p.V600E (c.1799T>A) in gene BRAF cause the sensitivity of GDC0879 by aberration of the drug's therapeutic target |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.